Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,287

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings

by Zacks Equity Research

OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.

Zacks Equity Research

Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat

by Zacks Equity Research

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.

Zacks Equity Research

Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y

by Zacks Equity Research

Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.

Zacks Equity Research

Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) third-quarter earnings reflect strong segmental performance.

Zacks Equity Research

Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat

by Zacks Equity Research

Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.

Zacks Equity Research

Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated

by Zacks Equity Research

Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.

Zacks Equity Research

AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong

by Zacks Equity Research

Globus Medical's (GMED) spinal implant business performance varies by region in Q3.

Zacks Equity Research

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.

Zacks Equity Research

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

ABIOMED's (ABMD) international Impella revenues improved in Q2.

Zacks Equity Research

CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3

Zacks Equity Research

Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.

Zacks Equity Research

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

Zacks Equity Research

AngioDynamics (ANGO) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Here's Why You Should Add AngioDynamics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

Zacks Equity Research

AngioDynamics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in AngioDynamics.

Zacks Equity Research

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.

Zacks Equity Research

AngioDynamics (ANGO) in Focus: Stock Moves 6.2% Higher

by Zacks Equity Research

AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

AngioDynamics (ANGO) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 6.95%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AngioDynamics Unveils Auryon Atherectomy System for PAD

by Zacks Equity Research

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

Zacks Equity Research

Why Is AngioDynamics (ANGO) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for August 5th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

New Strong Sell Stocks for August 3rd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today